Blueprint Medicines Corporation provided revenue guidance for the year 2022. The company continues to anticipate approximately $180 to $200 million in total net revenues in 2022, including approximately $115 to $130 million in AYVAKIT net product revenues.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
92.26 USD | -0.03% | +7.17% | +0.02% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+0.02% | 5.65B | |
+4.09% | 43.43B | |
+47.81% | 41.69B | |
+9.45% | 41.31B | |
-10.92% | 27.14B | |
+9.32% | 25.28B | |
-24.87% | 18.47B | |
+29.70% | 12.59B | |
+1.28% | 12.33B | |
+7.78% | 11.03B |
- Stock Market
- Equities
- BPMC Stock
- News Blueprint Medicines Corporation
- Blueprint Medicines Corporation Provides Revenue Guidance for the Year 2022